INDIRA TALWANI, District Judge.
Defendant InfoBionic, Inc., moved to dismiss or stay Plaintiff CardioNet, LLC's non-patent claims pending arbitration. Def. InfoBionic's Mot. Dismiss Pl. CardioNet's Non-Patent Claims Because CardioNet Is Obligated to Arbitrate Them, Or, in the Alternative, to Stay Those Claims Pending Arbitration [#190]. Having concluded that dismissal is improper,
CardioNet and Braemar Manufacturing, LLC filed this action against InfoBionic alleging patent infringement. CardioNet alleges three additional non-patent claims: misappropriation of trade secrets in violation of Mass. Gen. Laws ch. 93, § 42 and Massachusetts common law (Count VII); violation of the Pennsylvania Uniform Trade Secrets Act, 12 Pa. Cons. Stat. § 5301 et seq. (Count VIII); and unfair competition in violation of Mass. Gen. Laws ch. 93A and Pennsylvania common law (Count IX).
According to the operative complaint, Dr. Ravi Kuppuraj was employed by CardioNet from 2001 to 2002. During his tenure, Kuppuraj entered into multiple agreements with CardioNet, including a Confidentiality and Non-Disclosure Agreement, an At-Will Employment Agreement, and a Proprietary Information and Inventions Agreement. Kuppuraj subsequently left CardioNet and cofounded InfoBionic, where he became the Chief Technology Officer. As the underlying basis for its non-patent claims, CardioNet alleges that Kuppuraj "improperly accessed, copied, removed, and/or retained" confidential information upon leaving CardioNet in breach of the aforementioned contractual agreements. According to CardioNet, Kuppuraj provided the information to InfoBionic, and InfoBionic used this information in its product, the MoMe® Kardia System, without CardioNet's consent.
InfoBionic's pending motion seeks to stay the claims on the basis of an arbitration agreement between Kuppuraj and CardioNet. The arbitration agreement, which is attached as an addendum to the At-Will Employment Agreement, reads in pertinent part:
The agreement "remain[s] in full force and effect," pursuant to a severance agreement Kuppuraj and CardioNet entered into at the conclusion of his employment in 2002.
InfoBionic acknowledges that it is not a signatory to the arbitration agreement between Kupparaj and CardioNet but contends that CardioNet's non-patent claims against InfoBionic are referable to arbitration under the agreement on the basis of equitable estoppel. CardioNet responds that InfoBionic is not entitled to rely on the agreement between CardioNet and Kupparaj, that the claims do not fall within the scope of the agreement,
The Federal Arbitration Act, 9 U.S.C. § 3, allows a party to seek a stay on the ground that an issue is referable to arbitration under an agreement in writing for such arbitration. Under this section, the court, "upon being satisfied that the issue involved . . . is referable to arbitration under such an agreement, shall on application of one of the parties stay the trial of the action until such arbitration has been had in accordance with the terms of the agreement, providing the applicant for the stay is not in default in proceeding with such arbitration."
"[A] party cannot be required to submit to arbitration any dispute which [it] has not agreed so to submit."
As a non-signatory to the arbitration agreement, InfoBionic seeks to invoke its provisions under the doctrine of equitable estoppel under California law.
Claims depend upon the underlying contractual obligations when they "rely on or use . . . terms or obligations of the . . . agreement[] as a foundation."
A claim may be founded in and inextricably intertwined with underlying contractual obligations "when the signatory raises allegations of `not merely parallel or similar, but substantially interdependent and concerted misconduct by both the non[-]signatory and one or more of the signatories to the contract.'"
Examining each claim individually, the court concludes that InfoBionic is entitled to invoke the arbitration agreement between Kuppuraj and CardioNet.
CardioNet brings misappropriation claims under both Massachusetts statutory and common law. To establish a claim under the Massachusetts trade secret misappropriation statute, CardioNet must demonstrate that InfoBionic "embezzle[d], st[ole] or unlawfully t[ook], carrie[d] away, conceal[ed], or copie[d], or by fraud or by deception obtain[ed], from any person or corporation, with intent to convert to his own use, any trade secret, regardless of value." Mass. Gen. Laws ch. 93, § 42. To succeed on its common law claim, CardioNet must show that the information at issue constituted a trade secret, that it "took reasonable steps to preserve the secrecy of" that information, and that InfoBionic "used improper means . . . to acquire and use the trade secret."
The crux of CardioNet's misappropriation claims is that CardioNet obtained the trade secrets improperly because Kuppuraj purportedly breached his contractual agreements and confidential relationship with CardioNet. Because the impropriety alleged was the breach itself, the question of InfoBionic's liability is inextricably bound up with the alleged breach.
Importantly, CardioNet does not allege that InfoBionic obtained the trade secrets through any means other than Kuppuraj's breach of his contractual agreements. CardioNet has not alleged that InfoBionic's employees, while acting as InfoBionic's employees, somehow improperly obtained the trade secrets from CardioNet, or that CardioNet improperly obtained them from Kuppuraj.
In its opposition, CardioNet asserts that the alleged wrongdoing extends beyond Kuppuraj's misappropriation of source code and breach of contract and that the misappropriation claims would be viable even if Kuppuraj never had entered into the contractual agreements with CardioNet. However, the court must focus on the facts as alleged in the complaint.
Further, CardioNet's assertion that Kuppuraj breached a common law duty to CardioNet, apart from any contractual duty, fails because the arbitration agreement encompasses common law claims as well.
Given that the misappropriation claims are founded in and inextricably intertwined with Kuppuraj's obligations to contracts that are the subject of the arbitration agreement, the misconduct alleged falls within the scope of the arbitration agreement.
CardioNet next alleges violation of the Pennsylvania Uniform Trade Secrets Act, which prohibits the "acquisition of a trade secret of another by a person who knows or has reason to know that the trade secret was acquired by improper means." 12 Pa. Cons. Stat. § 5302;
Count IX alleges that InfoBionic engaged in unfair methods of competition in violation of the Massachusetts Consumer Protection Act, Mass. Gen. Laws ch. 93A, and Pennsylvania common law.
The arbitration agreement provides an exception for "claims . . . for injunctive and/or other equitable relief (remedies requiring a court's rapid injunctive power)." CardioNet argues that, because it seeks injunctive and declaratory relief in addition to monetary damages for each of the non-patent claims, its claims are entirely exempt from arbitration.
Although CardioNet has included a demand for preliminary injunctive relief in its complaint, CardioNet has not moved for preliminary injunctive or other relief requiring the court's "rapid injunctive power." And what CardioNet labels as "claims" for injunctive or equitable relief are simply remedies found in the prayer for relief which CardioNet could continue to pursue at the conclusion of the arbitration if consistent with the arbitrator's decision on liability.
The question remains as to whether InfoBionic is in default in proceeding with arbitration.
The court is troubled by the absence of any steps by InfoBionic to formally initiate arbitration. Nonetheless, InfoBionic's affirmative defense based on the arbitration agreement in its answer when Plaintiffs first raised these claims places a "heavy" burden on CardioNet to prove waiver.
For the foregoing reasons and for the reasons stated in the March 1, 2017,
IT IS SO ORDERED.
To prevail on a common law unfair-competition claim, CardioNet must show (1) "the involvement of goods or services"; (2) "a false description or designation of origin with respect to the goods or service involved"; and (3) "a reasonable basis for the belief that one has been injured."